Evidence item

The absence of a randomized control arm limits definitive comparison with standard care. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 15122

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:b73684a68f4ea6fdc2ce0be10cf4442eddc6bcbb63d44981e59b13a0688528c7

This study had some limitations. Firstly, the single-arm, nonrandomized design without a control arm limits definitive comparison to the current standard of care.